Trial of 8,000+ people finds cardiovascular drug

Open benchmark tests whether AI can reason acros

A biotech partnership is using AI to hunt for a

A liver disease that kills faster than most canc

As hormones shift in midlife, brain, metabolic a

A breathable treatment for a disease that slowly

Eisai has received regulatory approval in Japan f

On 17 Sept.

MitoRx Therapeutics will present new preclinical

Cala Health has been named to TIME and Statista’s World’s Top HealthTech Companies 2026 list in the Medical Devices and Wearables category. The designation follows TIME and Statista research that recognizes 500 healthtech companies across six market segments and evaluates financial performance, reputation and online engagement. According to the company, its Cala TAPS therapy, delivered from a wrist-worn wearable, is the most researched wearable treatment for essential tremor. The U.S. Food and Drug Administration cleared the Cala kIQ Plus system earlier this year for action hand tremor in essential tremor and Parkinson’s disease, and the company claims kIQ Plus introduces new therapy modes and adaptive calibration to personalize treatment. The Cala system is available through the Veterans Affairs health system at no cost to eligible beneficiaries and has Medicare coverage for those who meet local coverage criteria, and the company continues to seek expanded reimbursement. The post Cala Health recognized among TIME’s top healthtech companies of 2026 appeared first on Longevity.Technology.

Loyal reported that LOY-003 has completed the Rea

Allergan Aesthetics, an AbbVie company, presented

Ultrahuman launched the HealthEx PowerPlug, a new

Aspen Neuroscience announced the publication in C

International Longevity Day will see scientists,

PURR-001 increased body mass and muscle thicknes

PURR-001 increased body mass and muscle thicknes

Insilico’s new program combines AI, circular m

AliveCor’s new KardiaACCESS program offers Med

AliveCor’s new KardiaACCESS program offers Med

Biosplice’s lorecivivint, which may slow rathe

Biosplice’s lorecivivint, which may slow rathe

Amprion has launched SAAmplify-αSYN Plus, a next

A peer-reviewed paper published in the Internatio

Insilico Medicine published a study in Cell intro

Rubedo Life Sciences announced a clinical study o

Cumulus Neuroscience presented three posters at t

AI model that reads heart scans becomes the firs

$71 million facility in Vilnius will manufacture

The company has launched The Elysium Longevity I

Inside the assumptions and interactive model beh

Nanoscope Therapeutics announced that Christine K

AliveCor has launched KardiaACCESS, a 10-year ini

NkGen Biotech will present on troculeucel at the

Twelve candidate aging rate indicators could off

Company bets that AI-assisted analysis and a lea

Durham University spinout Magnitude Biosciences

Yale-led analysis harmonized 51 studies under on

Cara Cassino spent a year advising Oligomerix fr

Our new report maps more than 3,000 therapeutic

At a Munich cardiology congress, a Korean startu

Lysoway Therapeutics announced the publication of

Heartseed is developing regenerative cell therapi

Tulu Health has launched in the US, betting that

PhytoGaia spotlights new clinical data on ingred

After reconsidering, Canada’s Drug Agency issu

New Princeton lab gives skincare-focused biotech

A Tohoku University team just won $1 million in

Berkeley biotech’s stem cell rejuvenation plat

The U.S.